Tonix Pharmaceuticals Uplists to Nasdaq Global Select Market in 2026

Tonix Pharmaceuticals (NASDAQ: TNXP) has achieved a significant corporate milestone by securing approval from Nasdaq to transfer its common stock listing from the Nasdaq Capital Market to the more prestigious Nasdaq Global Select Market. This uplisting, set to commence trading under the existing "TNXP" ticker symbol at market open on March 3, 2026, signifies the company's compliance with the higher tier's rigorous financial and corporate governance standards. Management heralds this move as a key step in enhancing institutional visibility, improving stock liquidity, and gaining broader market recognition, all aimed at fostering growth and creating shareholder value. The announcement was disseminated through the InvestorBrandNetwork, a platform within the Dynamic Brand Portfolio that provides extensive corporate communications solutions, including access to a vast network of wire solutions via InvestorWire and article syndication to over 5,000 outlets.

Tonix Pharmaceuticals Holding Corp. is a fully-integrated, commercial-stage biotechnology firm with a sharp focus on developing treatments for central nervous system (CNS) disorders and immunology conditions that address high unmet medical needs. The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), represents a breakthrough as the first new fibromyalgia treatment approved in over 15 years. Beyond this, Tonix's commercial infrastructure supports other marketed products like Zembrace® SymTouch® and Tosymra® for acute migraine. Its robust pipeline includes Phase 2 clinical trials exploring TONMYA's potential for major depressive disorder and acute stress disorder, alongside TNX-2900, which is Phase 2 ready for Prader-Willi syndrome. The immunology portfolio features promising candidates such as TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor targeting kidney transplant rejection prevention, though all remain investigational and unapproved.

This news was highlighted by TinyGems, a specialized communications platform under the IBN umbrella that focuses on innovative small-cap and mid-cap companies with significant growth potential. TinyGems leverages a comprehensive suite of services, including enhanced press release enhancement and social media distribution via IBN to millions of followers, to amplify client visibility. By cutting through market noise, TinyGems helps companies like Tonix gain unparalleled recognition and brand awareness, ensuring their stories reach a wide audience of investors, journalists, and the general public. For ongoing updates, stakeholders can visit the company's newsroom or subscribe to alerts, underscoring the strategic role of platforms like TinyGems in today's dynamic financial landscape.